Skip to main content

Table 7 Comparison of common AEs in two groups (n, %)

From: Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

 

Chemotherapy Group

(n = 30)

Immunotherapy Combined Chemotherapy Group

(n = 30)

P

(Grade 1 ∼ 4)

P

(Grade 3 ∼ 4)

Type of AEs

Grade 1 ∼ 4 (n)

Grade 1 ∼ 4 Incidence (%)

Grade 3 ∼ 4 (n)

Grade 3 ∼ 4 Incidence (%)

Grade 1 ∼ 4 (n)

Grade 1 ∼ 4 Incidence (%)

Grade 3 ∼ 4 (n)

Grade 3 ∼ 4 Incidence (%)

Overall Incidence

30

100

14

47

30

100

18

60

1.000

0.301

RCCEP

0

0

0

0

24

80

0

0

<0.001

1.000

Anemia

19

63

3

10

23

77

4

13

0.260

1.000

Decreased White Blood Cell Count

17

57

3

10

22

73

6

20

0.176

0.472

Decreased Neutrophil Count

18

60

6

20

21

70

6

20

0.417

1.000

Decreased Lymphocyte Count

13

43

5

17

17

57

6

20

0.302

0.739

Hypoalbuminemia

16

53

0

0

15

50

1

3

0.796

1.000

Decreased Platelet Count

14

47

2

7

12

40

2

7

0.602

1.000

Hyponatremia

14

47

0

0

11

37

0

0

0.432

1.000

Hypothyroidism

1

3

0

0

10

33

0

0

0.003

1.000

Pneumonia

10

33

4

13

10

33

7

23

1.000

0.317

Hyperuricemia

6

20

0

0

8

27

0

0

0.542

1.000

Vomiting

6

20

0

0

8

27

1

3

0.542

1.000

Diarrhea

2

7

0

0

6

20

1

3

0.254

1.000

Hyperlipidemia

2

7

0

0

5

17

0

0

0.424

1.000

Rash

0

0

0

0

5

17

0

0

0.052

1.000

Constipation

0

0

0

0

5

17

0

0

0.052

1.000

Elevated Blood Urea

4

13

0

0

4

13

0

0

1.000

1.000

Elevated Creatinine

1

3

0

0

4

13

0

0

0.353

1.000

Dizziness

1

3

0

0

4

13

0

0

0.353

1.000

Insomnia

0

0

0

0

4

13

0

0

0.112

1.000

Hypokalemia

4

13

0

0

3

10

0

0

1.000

1.000

Abdominal Pain

3

10

0

0

3

10

0

0

1.000

1.000

Fatigue

1

3

0

0

3

10

0

0

0.612

1.000

Esophageal Fistula

3

10

3

10

2

7

2

7

1.000

1.000

Elevated ALT

4

13

0

0

2

7

0

0

0.671

1.000

Elevated AST

4

13

0

0

1

3

0

0

0.353

1.000